Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Secnidazole is a nitroimidazole antimicrobial agent used primarily to treat bacterial vaginosis and trichomoniasis in patients 12 years of age and older. It is a broad-spectrum antibiotic effective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa such as *Trichomonas vaginalis*, *Entamoeba histolytica*, and *Giardia lamblia*. The drug acts by entering the target pathogen where its nitro group is reduced by microbial nitroreductase enzymes to generate reactive intermediates that damage DNA helix structure, disrupt protein synthesis and replication, leading to cell death. Secnidazole is administered orally (typically as granules) in a single dose regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on secnidazole.